Participant flow

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2014-07-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.

   id

   FG000

   title

   Treatment (Enzyme Inhibitor Therapy)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         51

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice